Administration approval (postmarket surveillance) is crucial to protect public health. Device malfunction can result in serious injury and even fatality. [1] [2] [3] In contrast to medications, implantable medical devices pose unique challenges to effective postmarketing safety surveillance. These challenges include the complex interactions among devices, concurrently administered medications, existing patient comorbidities, and the effect of operator learning in the safe and effective use of the device. Postmarketing device safety surveillance is further complicated because the approval of a medical device often triggers rapid and widespread use in real-world patient populations. These populations are more diverse and complex than those studied in the controlled settings of clinical trials and premarket evaluations. [4] [5] [6] Postapproval surveillance strategies in the United States rely on a combination of mandatory and voluntary adverse event reporting systems, including MedSun, MedWatch, MAUDE, MDR, and FAERS, 7-10 as well as Food and Drug Administration mandated postapproval studies after initial market release. 11 Although these reporting systems are vital in identifying unexpected and unique adverse events, they have a dependence on voluntary, and inconsistent, reporting of adverse events by physicians and hospitals. Consequently, event under-reporting Background-Current approaches for postmarket medical device safety surveillance are limited in their ability to produce timely and accurate assessments of adverse event rates. Methods and Results-The Data Extraction and Longitudinal Trend Analysis (DELTA) network study was a multicenter prospective observational study designed to evaluate the safety of devices used during percutaneous coronary interventions. All adult patients undergoing percutaneous coronary intervention from January 2008 to December 2012 at 5 participating Massachusetts sites were included. A safety alert was triggered if the cumulative observed adverse event rates for the study device exceeded the upper 95% confidence interval of the event rates of propensity-matched control cohort. Prespecified sensitivity analyses were developed to validate any identified safety signal. A total of 23 805 consecutive percutaneous coronary intervention procedures were evaluated. Two of 24 safety analyses triggered safety alerts. Patients receiving Perclose vascular closure device experienced an increased risk of minor vascular complications (relative risk, 4.14; P<0.01) and any vascular complication (relative risk, 2.06; P=0.01) when compared with propensitymatched patients receiving alternative vascular closure device, a result primarily driven by relatively high event rates at 1 participating center. Sensitivity analyses based on alternative risk adjustment methods confirmed a pattern of increased rate of complications at 1 of the 5 participating sites in their use of Perclose vascular closure device. Conclusions-The DELTA network study demonstrates that distributed automated prospective safety surveillance has the potential of providing near real-time assessment of safety risks of newly approved medical devices. (Circ Cardiovasc Qual Outcomes. 2015;8:38-46.
and lack of available denominator data on the total number of devices implanted result. 12 Postapproval studies have historically had low execution rates because of a variety of challenges, and frequently do not cover a broad range of longer term outcomes. [13] [14] [15] These limitations are well known; the Food and Drug Administration recently released a roadmap for strengthening the national medical device postmarket surveillance system, which includes developing additional capacity in automated signal detection and surveillance methodologies and deploying prospective surveillance networks. [15] [16] [17] We developed a set of automated surveillance tools, denoted Data Extraction and Longitudinal Trend Analysis System (DELTA) and validated the methods and informatics infrastructure within a variety of retrospective data sources from clinical databases, [18] [19] [20] as well as randomized controlled clinical trials. 21 Prospective use of DELTA has not been studied.
We sought to assess the operating characteristics of DELTA when used prospectively. We deployed this tool set using advanced data deidentification and sharing methods, and a variety of robust statistical techniques for continuous surveillance of clinical registries to identify low-frequent safety signals. 22 To our knowledge, prospective execution of this type of automated approach to medical device surveillance has not previously been described. The DELTA Network Study (DELTA-NS) is a multicenter, prospective, observational research study using a distributed network architecture for data collection, designed to evaluate the safety of new cardiovascular devices used during percutaneous coronary intervention (PCI). 23 Participating institutions used the National Cardiovascular Data Registry (NCDR) CathPCI data collection instrument 24 to facilitate secure, deidentified, clinical data submission to a central DELTA server for prospective safety analyses. The primary objective of the study was to monitor the safety of devices used during PCI procedures for higher than expected adverse event rates. We monitored newly approved drug-eluting coronary stents (DES), coronary embolic protection devices (EPD), and vascular closure devices (VCD) in patients undergoing PCI.
Methods
A detailed description of the DELTA network study design has been published previously. 23 In brief, the DELTA surveillance network was developed as a 2-tiered network of secure database servers, with remote DELTA agents installed at 5 independent centers performing PCI in Massachusetts. Each remote DELTA agent was responsible for deidentification of all personal health information, as well as HIPAA compliant and secure information transfer to a central DELTA server located in the Partners Healthcare Research computing center. The central DELTA server conducted the prospective safety analyses, generating safety alerts and other messages that were transmitted via e-mail to the DELTA agent at the participating site. In addition to full deidentification of personal health information, information sent to the central DELTA server was stripped of physician and center identifiers to preserve complete anonymity of participating physicians.
Eligibility Criteria and Data Collection
All patients aged ≥18 years who underwent PCI at one of the participating centers between January 1, 2010, and December 31, 2012, were included in the study. The participation of each site was reviewed and approved by each local institutional review board, whereas the overall study was reviewed and approved by the Partners Healthcare institutional review board. Informed consent requirements were waived on the basis of minimal risk to individual patients through secondary research use of their deidentified clinical data.
All participating sites used their NCDR-certified CathPCI data submission software that was used for state-mandated quarterly submission of PCI data set files to the Massachusetts Data Analysis Center. The same data format was used to submit information to the DELTA-NS. Clinical information was entered, per the previously used centerspecific workflow, by trained data managers or their designees, and uploaded to the local DELTA agent on a quarterly basis. Because the same data set format was, by design, used by DELTA as was used to submit data sets to Massachusetts Data Analysis Center, data management teams only entered data once. Retrospective data for PCIs performed between January 1, 2008, and December 31, 2009, were pooled with the prospectively collected data to increase specific device exposure sample size and to facilitate propensity-matched analyses.
Device Exposures and Adverse Outcomes
We evaluated the acute postprocedural safety of 3 types of medical devices used routinely in interventional cardiology practice. These included (1) 2 new DES (Abbott Vascular Xience stent and Medtronic Endeavor stent), (2) 2 new EPD (Boston Scientific FilterWire and EV3 Spider), and (3) 4 VCD (St. Jude Medical AngioSeal, Access Mynx, Abbott Perclose Proglide, and Abbott Vascular StarClose). Distinct products, as listed in the NCDR CathPCI intracoronary devices and vascular closure devices tables that represented only incremental changes in device design, were grouped into device families to increase sample size, and therefore analytic power. The implant or active component of the device was the same within each device family, with only minor differences in the device delivery system appearance.
Each medical device was evaluated for risk-adjusted adverse outcomes specific to the device type (ie, DES, VCD, or EPD). The adverse events for stents and EPD included in-hospital death, in-hospital postprocedural myocardial infarction, and a composite of major adverse cardiac events, including in-hospital death, postprocedural myocardial infarction, stroke or unplanned coronary revascularization. For the VCDs, adverse events included in-hospital minor vascular complications (including groin bleeding, hematoma >5 cm, pseudoaneurysm, and arteriovenous fistula), major vascular complications (including retroperitoneal hemorrhage, limb ischemia, and any surgical
WHAT IS KNOWN
• Current strategies used for assuring that newly approved medical devices are safe, relative to other devices and therapies, rely primarily on passive and voluntary reporting of adverse events by providers and healthcare institutions. • Prospective active safety surveillance of medical devices relying on clinical registries has been shown to identify safety signals that have not been uncovered through passive reporting mechanisms.
WHAT THE STUDY ADDS
• Through the prospective monitoring of a network of participating hospitals in Massachusetts, the current study demonstrates that prospective active safety surveillance of medical devices is both feasible and can be performed in near real-time. • Importantly, in addition to potential identification of device-specific safety differences, significant variation in patient selection for the use of specific devices among the participating centers significantly influenced device-specific outcomes.
or interventional repair), and any vascular complication. On the basis of historical adverse event rates from the Massachusetts statewide statistics, 20 we determined that the analyses would have 1-sided power to detect a 50% increase in composite adverse events, using a 10% α error, ranging from 72% for EV3 Spider EPD to 99% for the Xience DES, and 10 of the 18 device-outcome analyses would have a power of >85%.
Propensity Score Matching and Statistical Methods
A propensity-matched comparison population was developed for each device-outcome analysis, based on previously published risk factors for the outcome of interest, as well as factors considered by domain experts to influence the selection of one device versus another potentially. A complete list of variables included in the propensity match analysis of each class of device has been published previously 23 and is provided in the Data Supplement Appendix. Propensity scores were developed using nonparsimonious logistic regression models developed with the device of interest (exposure) used as the dependent variable, adjusting for the specified variables. Matching cases were randomly selected in a 1:1 ratio, within 6 months of the date of the exposed case, using a fixed propensity score caliper width of 0.05 as previously validated. 20, 23, 25 Adverse event rates were calculated quarterly for the propensity score-matched cohorts for each device-outcome analysis. The cumulative number of events per quarter was used to calculate a difference of proportions between the 2 groups by the Wilson method. 25 If the confidence intervals of point estimates of the difference of proportions did not cross zero, a statistically significant difference between the comparison and exposed groups was detected. Safety alerts were triggered if the cumulative event rates in the exposed group exceeded the upper confidence limit of the event rates in the comparison group by >20% (selected to represent a clinically meaningful difference in safety profile), using 95% confidence intervals, corrected for type I error inflation using the O'Brien-Fleming α-spending method. Importantly, the propensity-matched cohort comparison, as used in this study, inherently compares the relative safety of one device to that of a comparator device in a population of similar patients and cannot be used to assess absolute safety relative to expected performance or previous experience directly.
Any device-outcome analysis that generated ≥2 consecutive safety alerts during cumulative monitoring was considered a sustained alert and prompted detailed sensitivity analyses, using alternative risk adjustment methods, as previously described, 23 to verify, or refute, the adverse safety signal identified using the propensity-matched analysis. Procedures for the propensity score model and statistical analysis were performed by the integrated open-source Observational Cohort Event Analysis and Notification System (http://sourceforge.net/projects/oceans/) developed to provide biostatistics processing support for automated surveillance. All algorithms used have been validated against SAS version 9.1 (Cary, NS). All statistical tests were 2 sided, with P<0.05 considered statistically significant for all comparisons.
Results
A total of 23 333 PCI cases were performed between January 1, 2008, and December 31, 2012, at the 5 participating sites. Among the 8 devices studied, 3 adverse outcomes were monitored for each device, resulting in 24 separate simultaneous prospective safety analyses; each repeated on a quarterly basis throughout the study. Two analyses within the Perclose VCD analysis triggered sustained safety alerts. The remaining 7 devices (including the Xience DES, Endeavor DES, Filterwire EPD, Spiderwire EPD, AngioSeal VCD, Mynx VCD, and StarClose VCD) did not trigger any safety alerts throughout the study.
Tables 1 to 6 summarize the results of the safety analyses performed and the concurrent matched comparison populations chosen for each device safety analysis. The proportion of exposures successfully matched using the propensitymatching algorithm ranged from 40.2% for the Xience DES to 99.9% for the Mynx.
The relatively low match rate for the Xience DES was because of the use of Xience as the predominant DES within the participating sites, resulting in relatively fewer alternative DES to use as controls in the propensity match.
Exploration of Safety Alerts
Although there were no sustained safety alerts for any device studied within the DES or EPD device type analyses, there were sustained alerts triggered for the Perclose VCD, as well as high relative event rates noted for the Mynx VCD, although this analysis did not reach statistical threshold for triggering a sustained alert. The Perclose family of VCD was used in 2539 procedures, of which 2489 (98%) were successfully matched to comparison procedures receiving alternative VCD (Tables 5   Table 2 . and 6). A safety alert for the Perclose family of VCD related to an increased risk of minor vascular complications was first triggered at Q3 2010 (after accruing 1575 cases) and continued through completion of the study (total exposures, 2539 cases). The safety alerts included an increased risk of both minor vascular complications ( Figure 1 ) and any vascular complication ( Figure 2 ). By the end of the study period, the relative risk of minor vascular complications was 4.14 (P<0.001) with the use of the Perclose VCD compared with propensity-matched patients receiving alternative VCDs. Similarly, the relative risk of any vascular complication was 2.06 (P=0.01) with Perclose VCD versus alternative VCD, a result driven by the increased risk of minor vascular complications observed. Baseline disparities between patients receiving Perclose VCD and those receiving alternative VCD were eliminated for most covariates after the propensity match was applied ( Table 7) although differences remained in the proportion of patients with previous peripheral arterial disease, patients presenting with ST-segment-elevation myocardial infarction and those undergoing left main PCI. There were no significant differences between Perclose VCD when compared with alternative VCD with respect to the rate of major vascular complications. Prespecified sensitivity analyses were performed per study protocol to explore the safety signals detected for Perclose VCD further. A multiple logistic regression predictive model for the risk of minor vascular complications, based on the cohort of all non-Perclose VCD used in 2008, was developed and applied prospectively to the entire cohort of patients receiving Perclose VCD. We observed no significant difference between the alerting behavior using the logistic regression predictive model versus the original propensity match analysis, thereby supporting the findings of the primary propensity analysis. Examination of the incidence of minor vascular complications according to participating site was conducted and indicated that the increased risk for minor vascular complications was driven exclusively by a substantially increased risk at 1 of the 5 participating centers. Further subgroup analysis demonstrated that, among the patients in whom a VCD was used, the outlier institution treated a similar proportion of patients who had PAD when compared with the other participating centers (12.8% versus 10.6%; P=0. 14) , whereas the outlier center used Perclose significantly less often than alternative VCDs in these patients with PAD (69.2% versus 95.3%; P<0.001).
About the Mynx family of VCD, a nonsignificant trend toward increased rate of any vascular complication was observed in Q3 2010 (after accruing 687 cases), with a relative risk of 2.20 when compared with alternative VCD (P=0.13). However, there was limited use of the Mynx device in clinical practice at the participating sites and use declined considerably after 2010, which made this analysis underpowered to confirm the presence of a sustained safety signal in the use of the Mynx device.
Discussion
The DELTA Network Study used a novel approach of prospective postmarketing safety surveillance of recently approved medical devices through continuous sharing and transmission of deidentified clinical data by a network of independent medical centers, along with automated, near-real-time comparative safety analysis. The existing NCDR CathPCI data collection instrument was used to minimize the need for customization of the local database interface, which permitted seamless integration of the DELTA surveillance system into each institution's quality monitoring procedures.
No safety alerts were identified for either the 2 recently approved DES (Abbott Vascular Xience stent and Medtronic Endeavor stent) or the 2 commonly used EPD (Boston Scientific FilterWire and EV3 Spider). However, increased rates of minor and any vascular complications (but not major vascular complications) with use of Perclose VCD compared with propensitymatched alternative VCD were observed. The findings were sustained after temporal trend analyses and application of alternative risk models via multivariate logistic regression adjustment. Further exploration of the rates of vascular complications in the use of Perclose at the participating sites enabled identification of a single outlier site that had an unusually high rate of vascular complications with use of Perclose VCD. This outlier site was notified of the safety signal and has implemented additional device training and quality improvement initiatives intended to improve the safety in the use of the device. The identification of a single outlier site as the driving factor in generating the safety signal for Perclose VCD likely indicates that safety concern was likely a result of case/patient selection or operator training at the outlier site, rather than an indication of intrinsic safety concerns for the Perclose device itself. In addition, the identification of a single outlier site highlights the critical importance of prespecification of sensitivity, subgroup, and secondary end point analyses, to provide the most robust and valid interpretation of any safety signals generated by the primary analyses during a prospective safety study. Putting these findings into context, it is important to recognize that, although there are few comparative data on the safety of various VCD, a previous meta-analysis and multiple large observational registry studies have found the Perclose VCD to be safe with no increase in the incidence of vascular complications compared with alternative VCD or manual compression. 26 Although a safety signal was identified in this analysis, it is more likely that this signal represents residual confounding because of case selection or training at the single, outlier, center, rather than an intrinsic safety concern with the Perclose device itself. In addition, the current analysis was not designed to account for the experience of specific operators in the use of particular devices. The effect of device-specific learning has been shown to influence VCD clinical outcomes significantly 27 and differences in experience between providers at the participating centers cannot be excluded as potentially affecting the results observed. In addition, the DELTA-NS identified a nonsignificant trend toward increased rate of vascular complications with the use of the Mynx family of VCD, relative to propensity-matched patients receiving alternative VCD. This analysis was underpowered because of the significant decline in the use of the Mynx device during the course of the study (Figure 3 ). One possible explanation for the dramatic reduction in the use of the Mynx device was the observation of the higher than anticipated vascular complication in patients receiving the device on the part of the treating interventional cardiologists at the participating centers, leading to decreased use of this device.
A strategy of prospective device safety surveillance through continuous analysis of high-quality clinical registries, as validated by the DELTA network study, has the potential to identify low-frequency safety signals through the simultaneous monitoring of numerous high-risk devices by pooling detailed clinical data from multiple institutions. Such a strategy represents a substantial change from current approaches to the routine monitoring of postmarket safety of medical devices. Current device safety surveillance methods used by public health officials principally rely on passive reporting of adverse events by patients, physicians, manufacturers, and healthcare organizations. These passive surveillance systems have event under-reporting and lack denominator data on comprehensive exposure. 12, 15 Other more recent mechanisms for monitoring device safety, including federally mandated postapproval clinical registries frequently have limited, or no, control populations and often lack statistical power to detect low-frequency safety signals. [12] [13] [14] [15] The DELTA-NS approach may, therefore, complement future prospective postmarketing surveillance approaches evaluating the safety and efficacy of medical devices through the monitoring of routinely collected clinical data. Although such automated safety surveillance tools will initially depend on detailed clinical registries, future efforts should also be directed toward the routine monitoring of clinical data extracted from electronic health record (EHR) systems. Automated prospective surveillance of medical devices must overcome several important challenges to be used as an effective surveillance tool. Timely submissions of complete data by all participating sites with prompt adjudication and validation of alerts are essential. Any safety signal identified through automated safety surveillance must be interpreted with caution and explored in-depth by detailed sensitivity analyses and other rigorous epidemiological explorations. Such analyses are critical to investigate potential residual confounders of the observed outcomes and confirm that the preliminary safety alerts triggered by propensity score matching are likely true safety signals. In addition, it is important that alert-driven sensitivity analyses, subgroup analyses, and secondary end points be predefined in a clear and written safety surveillance analytic plan, to minimize the risks associated with multiple comparisons or the temptation of unstructured data exploration.
Limitations
By virtue of being a nonrandomized prospective observational study, the DELTA-NS has biases inherent to observational studies. Given the dependence on the NCDR CathPCI data collection instrument for data acquisition and submission, the scope of the clinical factors that were available for analysis was limited. Version 4 of CathPCI does not include vascular sheath size as a covariate in the data set, and therefore an imbalance in the use of large bore devices (>8 French) among centers or VCD populations cannot be excluded although unlikely because of the extremely rare use of such sheath sizes in contemporary practice at the participating sites. Similarly, the data set did not identify nonstandard VCD deployment such as the preclose technique using Perclose VCD, 28 which could have confounded the observed event rates. Likewise, the adherence of participating sites to the comprehensive reporting of postprocedural clinical events is essential to minimize ascertainment bias, as it is for all clinical registry-based studies. Also, for this study, clinical events were monitored only through the time of discharge, limiting the scope of any safety comparisons for the studied devices. Thus, potentially important late safety concerns, such as stent thrombosis (DES devices) or access site infections (VCD), could not be assessed. In addition, the collection of post-PCI biomarkers is variable across participating centers, thereby limiting the potential value of surveillance for outcomes, such as postprocedural myocardial infarction, based on analysis of this laboratory result. Although the data set used in this analysis was larger than many observational studies of interventional cardiology devices, it was significantly smaller than studies of national or regional registries and has a lack of generalizability because of the small number of participating centers. Finally, because this was a nonrandomized study in which patients might have been treated with multiple devices during a procedure, the ability to attribute a particular clinical outcome event to an exposure may have been confounded by simultaneous exposures to other devices or treatment decisions. Although propensity score matching were used to reduce the potential confounding between the population of patients exposed to a particular device and patients receiving alternative devices, the effectiveness of the matching process is inherently limited. In this study, there remained significant residual imbalance between the study cohorts within several covariates, including a history of peripheral arterial disease and increased fluoroscopy times, potentially indicating more complex procedures for patients receiving Perclose when compared with other VCD. These imbalances may have biased the results toward observing a higher rate of vascular complications in patients receiving Perclose. Potentially mitigating this bias, there were fewer Perclose patients treated for ST-segment-elevation myocardial infarction, which would have been expected to be associated with reduced vascular access site complications. In addition, propensity score matching led to the exclusion of variable number of exposures because of the inability to find adequate matched cohorts, thereby, limiting any comparative statements that can be made about device safety in these patient populations. Such inability to identify adequate matched controls for exposed cases may reflect either limited sample size or might imply truly different populations of patients receiving the device of interest, making comparisons with alternative devices more challenging. The comparison of cohorts of propensitymatched cases results in a comparison of the relative safety of one device to another, rather than an absolute assessment of safety when compared with previous experience or clinical trial experience. Thus, propensity-matched cohort analyses, as used in this study, could miss the identification of an adverse safety signal if the comparator group itself experienced a higher rate of adverse events than would have been initially expected. Finally, because the DELTA network was a pilot multicenter prospective surveillance study, it may have had insufficient power to detect a safety signal at the thresholds for alerting selected.
Conclusions
The DELTA-NS demonstrates the successful implementation of an automated prospective medical device safety surveillance study conducted within a network of participating clinical centers sharing routinely collected clinical registry data in near real-time. Such a strategy may offer substantial advantages over existing strategies used by US regulatory agencies. Early identification of clinical safety concerns through such automated surveillance could further support public health officials to identify the need for additional device-specific training, refinement of patient selection criteria, or initiation of comprehensive epidemiological exploration into inherent device failures, to reduce medical device-related risks to future patients. Figure 3 . The use of the Mynx vascular closure devices (VCDs) as a proportion of total VCD use during the study. Among the study sites, Mynx VCD use peaked at 17.8% of all VCD implants in the third quarter of 2009, followed by a sudden and dramatic decline in the use to a rate of <1% of all VCD by 2012.
